Key Highlights
- Nura Bio closes $140M Series A financing to support clinical development.
- Shilpa Sambashivan, Ph.D., appointed as CEO following Phase 1 success of NB-4746.
- NB-4746 is a brain-penetrant SARM1 inhibitor with potential neuroprotective benefits.
- Phase 1 trial results show NB-4746 was well-tolerated and achieved target plasma exposure.
Source: Business Wire
Notable Quotes
- “Under Shilpa’s leadership, Nura Bio has successfully transitioned to a clinical-stage organization, making remarkable progress in identifying ways to translate complex biology into potential therapies.” — Tim Kutzkey, Ph.D., Managing Partner at The Column Group
- “I look forward to leading the company through this next phase as we prepare to test the SARM1 hypothesis in a patient population in 2025.” — Shilpa Sambashivan, Ph.D., CEO at Nura Bio
SoHC's Take
The successful closing of over $140M in Series A financing for Nura Bio underscores the increasing investor confidence in the company’s neuroprotective research and therapeutic pipeline. With NB-4746 progressing successfully through Phase 1 trials, Nura Bio is well-positioned to address significant unmet needs in the treatment of neurological diseases. Shilpa Sambashivan’s appointment as CEO is a strategic move, leveraging her deep scientific expertise and leadership to guide the company toward achieving its ambitious clinical milestones in the coming years.
Heading
Episode Details: Join us on the latest episode, hosted by Jared S. Taylor! Our Guest: Dr. Jim Bonnette, Chief Medical ...
Key Highlights 28% reductionin documentation time for care teams20% increasein patient engagement through automated outreachAI Agentsmanage SMS/voice outreach, scheduling, and ...
Key Highlights Warner Roberts appointed as Calibrate’s Chief Commercial OfficerWill lead commercial strategy to scale workplace obesity solutionsCalibrate members report ...
Key Highlights Fully integratedwith Castlight’s healthcare benefits app 24/7 on-demand carevia chat, video, and voice High-quality carefor common conditions delivered ...
Episode Details: Join us on the latest episode, hosted by Jared S. Taylor! Our Guest: Peter Donnelly, CEO & Co-Founder ...
